Archived

Precision Mental Health: Develop Tools to Inform Treatment Selection in Depression (UG3/UH3 Clinical Trial Optional)

Federal funding opportunity RFA-MH-25-190 from National Institutes of Health (Department of Health and Human Services).

Posted: April 3, 2024
Closed: October 18, 2024
Cost sharing: No
Instrument: Cooperative Agreement
Assistance listing: 93.242
Category: Health
Archives: November 23, 2024

Program funding history

Awards made under Assistance Listing 93.242 across FY2025–FY2027, from public federal spending records.

FY2025 obligated: $1.8B
FY2026 obligated: $1.8B
FY2027 (to date) obligated: $0
Awards in window: 6,272

Top recipients: Yale Univ, University of Pittsburgh - of the Commonwealth System of Higher Education, Icahn School of Medicine at Mount Sinai, Trustees of the University of Pennsylvania, the, Washington University, the

Source: USAspending.gov · refreshed October 2026 · Program page: awards, recipients and the opportunities under this listing →

This opportunity is archived. Applications are no longer accepted. Similar grants are listed below, and the free Tuesday digest carries the next ones like it.

Synopsis

The purpose of this phased Notice of Funding Opportunity (NOFO) is to create a pipeline to accelerate the development and early validation of predictive tools and/or biomarkers to inform individual-level treatment selection among two or more existing therapeutics for depression. This phased inter-agency program will be milestone-based and provide support from multi-disciplinary teams to address scientific, technical, clinical, regulatory, and commercialization requirements. In the first phase (UG3), investigators are expected to identify potential tools and/or biomarker(s) that can predict whether a patient will differentially respond to one well-established depression treatment versus another. This could be accomplished using secondary analysis of data from completed clinical trials or using real-world clinical data, or by conducting small, efficient pilot feasibility studies to assess promising new tools or biomarkers to predict individual treatment response to a specific therapeutic for depression. In the second phase (UH3), investigators will conduct independent, prospective clinical trials to initially validate the utility of the tool/biomarker for predicting differential response to established treatments for depression. The overall goal of this NOFO is to support the testing of various tools/biomarkers as predictors of response to well-established depression treatments and halt the development of those tools that do not meet sufficient performance characteristics to justify further testing. Ultimately, tools that are successful in early-stage studies could be further evaluated for future use in decision-making in clinical practice settings.

Who can apply

County governments
Special district governments
Public and State controlled institutions of higher education
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Small businesses
Public housing authorities/Indian housing authorities
Independent school districts
State governments
Private institutions of higher education
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
For profit organizations other than small businesses
Native American tribal governments (Federally recognized)
Others (see text field entitled "Additional Information on Eligibility" for clarification)
City or township governments

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

The official record

Grants.gov published the official terms and dates of this opportunity; this page keeps them as they were listed.

View on Grants.gov Full announcement

Agency contact: National Institutes of Health · [email protected] · 301-402-2541

New to federal funding? How to read an announcement · Who can apply · How grants work

Tell me when this program posts again

This round has closed. One email the morning after this program is posted again under a new number (we watch for about two years), and one more about a week before that round closes (the next morning, if it is already closer than that). That is all this sends — it is not a newsletter signup.

Stored once per grant, used only for this watch’s emails; every one carries a one-click unsubscribe. Privacy

Get grants like this every Tuesday — free

One email a week: the biggest new federal grants and what’s closing soon — the same list for everyone. Unsubscribe any time.

No spam, ever. Privacy

Similar grants

Accelerating Solutions to Improve Access and Quality of Empirically-Supported Practices for Youth Mental Health (R01 Clinical Trial Optional)
PAR-25-310 · National Institutes of Health · closes January 7, 2027
Full-Scale Hybrid Effectiveness-Implementation Trials for Mental Health Interventions (R01 - Clinical Trial Required)
PAR-25-177 · National Institutes of Health · closes October 15, 2027
Pilot Hybrid Effectiveness-Implementation Trials for Mental Health Interventions (R01 Clinical Trial Required)
PAR-25-178 · National Institutes of Health · closes October 15, 2027
Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)
PAR-25-183 · National Institutes of Health · closes October 15, 2027
Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)
PAR-25-184 · National Institutes of Health · closes October 15, 2027
Effectiveness Trials to Test Mental Health System Interventions (R61/R33 Clinical Trial Required)
PAR-25-285 · National Institutes of Health · closes October 15, 2027

Same-day alerts, matched to you

The free digest is weekly — the same list for everyone. Members get every open federal grant scored to their organization — and an alert the day a real match posts: we read every new posting the day it opens. Free for 30 days, then $29/mo. Card required, cancel any time before day 31.

Not ready for a subscription? A one-time Fit Report — $29 — scores every open federal grant to your organization once, by email within one business day.

See pricing